Direct compression of EMBOCAPS FLEX on a 45-station rotary tablet press equipped with 10.0 mm round flat-faced bevel-edge tooling and a forced feeder requires pre-blending with glidant and lubricant in a 600 L bin blender. The blend is typically mixed for 12 min at 16 rpm; content uniformity is assessed according to USP <905> and Ph. Eur. 2.9.40. If the active fraction is classified as low-dose, 2 mg per unit or less, and the d90 of the API exceeds 150 µm, acceptance value may exceed 15.0 due to sampling variance in the final blend. Pre-lubrication with magnesium stearate at 0.25–0.50% w/w through a 0.5 mm screen is recommended; concentrations above 1.0% w/w reduce tablet breaking force and slow dissolution due to hydrophobic film formation. Powder flow is characterized using USP <1174> and Ph. Eur. 2.9.36; a compressibility index of 15–25% and a Hausner ratio of 1.15–1.25 are workable targets for consistent die fill. Compression force between 8 kN and 14 kN produces tablet breaking force of 80–140 N as measured by USP <1217>. Ejection force above 350 N may cause picking and lamination; this is observed when die wall lubrication is insufficient or when ambient relative humidity exceeds 60%. A compaction simulator program following USP <1062> is used to map tabletability before scale-up; at 85 rpm press speed, weight variation remains within ±5.0% for a 250.0 mg target tablet weight when die fill depth is controlled within ±0.15 mm. For materials with d10 below 20 µm, dry blending alone may produce poor content uniformity, making a wet or dry granulation route preferable.

The same direct compression process is used for film-coated tablets; the core is charged to a pan coater with 1.2 mm spray nozzle, inlet air at 60°C, atomization pressure of 1.5–2.0 bar, and pan speed of 6–12 rpm. Aqueous film coating with polyvinyl alcohol or hypromellose is applied to 3.0% w/w weight gain. If the API is moisture-sensitive, an organic-solvent hydroxypropyl cellulose system may be used instead; drying air dew point is then held below −10°C to prevent sticking. Process data from commercial scale indicate that core tablet hardness below 80 N leads to edge erosion in the pan coater, while hardness above 160 N slows disintegration below 15 min in 0.1 N hydrochloric acid at 37°C under USP <711> apparatus II at 50 rpm.

What Entrapment Efficiency Limits Arise in Low-Dose Capsule Filling?

On a 400,000 capsule per hour tamping pin capsule machine, the powder blend for EMBOCAPS FLEX is prepared with pregelatinized starch and sodium stearyl fumarate. The blend is passed through a 0.8 mm screen; pin stations are set to 5 tamping cycles with a powder bed depth of 12 mm. Low-dose capsule fill weight of 180 mg requires d50 between 75 µm and 180 µm, because finer fractions increase plug density but may cause flow stoppage in the feed frame, while coarser fractions reduce plug retention within dosator tubes. For dosator machines, powder plug formation is unstable if the Carr index exceeds 31% or if the flow function coefficient drops below 3.5 at consolidation stress 1.0–10.0 kPa as determined by ASTM D6773 ring shear testing. The fill weight relative standard deviation should be ≤ 2.0% for capsules with labelled content below 25 mg; this is evaluated across 20 consecutive capsules at start, middle, and end of the run. Content uniformity is assessed by USP <905> and Ph. Eur. 2.9.40; acceptance value ≤ 15.0 is required for the release assay.

Hard gelatin and hypromellose capsules are stored at 15–25°C and 35–55% relative humidity before filling; brittleness is observed below 35% relative humidity, while softening occurs above 55%. The process area is conditioned to 22°C and 45% relative humidity. Capsule shells are dedusted using a capsule polishing unit with 0.5–1.0 bar compressed air and then inspected under 3000 lux illumination for splits, dents, or air bubble defects. Dissolution of filled capsules is tested in 900 mL of 0.1 N hydrochloric acid with USP <711> apparatus II at 50 rpm; a minimum of 80% release at 30 min is commonly applied for immediate-release. If release is below 80% at 30 min, the formulation is checked for over-lubrication and for capsule shell cross-linking caused by aldehyde impurities in the shell.

Granule Porosity and Moisture-Mediated Re-Work in High-Shear Wet Granulation

A 10 L high-shear granulator equipped with an impeller at 200–400 rpm and a chopper at 1500–3000 rpm is used when direct compression fails due to segregation or poor compactibility. The dry binder is added at 3.0% w/w hypromellose or 5.0% w/w povidone K30, and water is sprayed to a liquid-to-solid ratio of 0.12–0.18 kg/kg. Endpoint is determined by impeller power consumption deviation; a plateau in the normalized power curve indicates granule formation, while a rapid rise indicates over-wetting. The wet mass is discharged through a 1.0 mm screen and dried in a fluid bed at inlet air 60°C, product temperature 38–42°C; final loss on drying is controlled between 1.0% and 2.5%. Granules with moisture above 2.5% may cause picking during tableting, while moisture below 1.0% may increase friability and lamination. Drying endpoint is confirmed by USP <921> Karl Fischer or loss on drying. The granule particle size distribution target is d50 120–200 µm; fines below 75 µm should not exceed 25% of total granule mass, as measured by USP <429> or Ph. Eur. 2.9.31. Granules are then milled through a 0.8 mm conical mill at 1500 rpm and blended with croscarmellose sodium at 2.0% w/w, followed by lubrication with magnesium stearate at 0.50% w/w for 3 min.

Tablets compressed from the milled granules at 12–18 kN produce breaking force of 100–150 N and disintegration times of 5–12 min in 900 mL water at 37°C according to USP <701>. Granule porosity, measured by mercury intrusion porosimetry, is typically 8–15%; lower porosity reduces water uptake and slows disintegration, while higher porosity lowers mechanical strength. If the API is hydrolytically labile, wet granulation is replaced by roller compaction unless forced degradation data from ICH Q1A conditions support aqueous processing. Hold time between wet mass and drying should not exceed 60 min unless stability data demonstrate no degradation. Re-work of rejected granules is limited to 15% of the total batch to avoid loss of compactibility due to work hardening; re-worked granules may also show increased fines and lower bulk density, requiring adjustment of die fill depth on the tablet press.

Dry granulation via roller compaction is applied when aqueous exposure is not acceptable. A roller compactor with 200 mm roll width and 250 mm roll diameter operates at roll force 10–25 kN/cm, roll speed 6–12 rpm, and gap 2.0–4.0 mm. Ribbon density is measured by envelope volume and is controlled between 1.1 g/cm³ and 1.4 g/cm³; ribbons with density below 1.0 g/cm³ generate excessive fines after milling. Milling is conducted through a 0.8 mm screen with an oscillating granulator at 80 rpm; granules with d50 150–300 µm and fines below 75 µm capped at 20% are preferred for downstream compression. The granulation is lubricated with sodium stearyl fumarate at 0.50% w/w; tablet hardness of 80–120 N is achieved at compression force 10–16 kN. Ribbon splitting at roll speeds above 12 rpm may occur due to air entrapment, which is visible as transverse cracks along the ribbon surface. If re-work of rejected ribbons is required, re-milling through a 0.8 mm screen with not more than 15% rework fraction avoids significant loss of compactibility. The roller compaction route is used for moisture-sensitive formulations and for blends that cannot be wet granulated due to polymorphic conversion risk. Critical process parameters are monitored with USP <1062> tablet compression characterization and Ph. Eur. 2.9.34 bulk density and tapped density testing; tapped density above 0.65 g/mL usually indicates dense granules that may require higher compression force or reduced press speed.

If Terminal Sterilization Is Not Feasible, Aseptic Filling of the Injectable Grade Remains the Primary Route

Injectable presentation of EMBOCAPS FLEX is prepared by dissolving the API in water for injection at a concentration of 5–20 mg/mL, buffered with 10 mM citrate or phosphate to pH 5.5–7.0. Osmolality is adjusted with sodium chloride to 280–320 mOsm/kg as measured by freezing point depression per USP <785>. The solution is passed through a 0.22 µm PVDF or PES filter at ≤ 0.5 L/min per 10 cm² membrane area; pre-filtration bioburden is maintained below 10 CFU/100 mL before sterile filtration. Filter integrity is tested by bubble point or diffusive flow as described in manufacturer technical bulletins and ISO 13408-1. If lyophilization is required, the product is filled into 10 mL type I borosilicate glass vials with 13 mm bromobutyl stoppers. Lyophilization cycle parameters are: freezing at −40°C for 3 h, primary drying at −20°C shelf temperature and 0.2 mbar chamber pressure for 24–36 h, secondary drying at 25°C for 6–12 h. Residual moisture by Karl Fischer is ≤ 3.0%. Container closure integrity is verified per USP <1207>; particulate matter is tested per USP <788>, and sterility is tested per USP <71>. The aseptic filling line uses 0.45 m/s unidirectional airflow in a Grade A zone; glove interventions are minimized to maintain Grade A particulate levels of ≤ 3520 particles per cubic meter at ≥ 0.5 µm and ≤ 20 particles per cubic meter at ≥ 5.0 µm under ISO 14644-1.

If ready-to-use injectable solution is required rather than lyophilized cake, the solution is filled under nitrogen overlay into 5 mL ampoules or vials. Dissolved oxygen is kept below 0.5 mg/L by sparging with nitrogen through a 0.22 µm filter; headspace oxygen is maintained below 5.0%. For light-sensitive formulations, amber glass vials providing 99% light transmission cutoff below 420 nm are used; stability is supported by ICH Q1B photostability data. Compatibility of the product solution with silicone tubing, stainless steel 316L, and elastomer stoppers is confirmed by extraction studies under 21 CFR 211.94 and ICH Q3C residual solvents guidance. Elemental impurities are controlled according to ICH Q3D; daily intake per drug product must not exceed permitted daily exposure limits for lead, arsenic, cadmium, and mercury. Sterile filtration of solutions above 20 mg/mL may require elevated temperature or reduced flow rate if viscosity exceeds 10 cP; published data for this specific configuration is limited, so filter capacity is determined by Vmax testing on small-scale membranes before production.

Directly Compressible Matrix Systems Display a Shear-Rate-Dependent Flow Function

Extended-release tablets using EMBOCAPS FLEX require a matrix former such as hypromellose 100 cP or 4000 cP at 20–40% w/w. Direct compression blend is processed through a V-blender at 24 rpm for 15 min; powder flow function coefficient values from ring shear cell testing according to ASTM D6773 are between 4.0 and 7.0 at consolidation stress 1.0–10.0 kPa, indicating cohesive-to-easy-flow material. Compression force of 10–20 kN yields tablets with hardness 90–160 N. Dissolution testing per USP <711> apparatus II at 50 rpm in 900 mL phosphate buffer pH 6.8 shows release over 12–24 h; lag times and burst release are controlled by the polymer ratio and particle size distribution of the matrix former. If the drug load exceeds 30% w/w, matrix integrity may fail due to percolation threshold effects; release becomes diffusion-limited only above polymer content 20% w/w. Avoid blending with a high-shear mixer above 300 rpm because this reduces matrix polymer particle size and shifts release toward faster initial dissolution. Tablet porosity below 10% slows drug release, while porosity above 20% increases burst release; porosity is controlled through compression force and tablet thickness. Data for this specific API grade in hypromellose matrices is limited; the numerical ranges are typical for poorly compressible BCS Class II actives and must be verified by a formulation design of experiments.

Matrix tablets are not subjected to film coating unless a lag time is required. If enteric protection is required, methacrylic acid-ethyl acrylate copolymer type C is applied to 10–15% w/w weight gain in a pan coater with 60°C inlet air and 1.5–2.0 bar atomization pressure. The coated tablets are tested for acid uptake in 0.1 N hydrochloric acid for 2 h; not more than 10% drug release is permitted before transfer to pH 6.8 buffer. The process is adjusted so that the final tablet weight variation remains within ±5% and thickness variation within ±0.2 mm. Equipment wear on the compression tooling is monitored because direct compression of polymer-rich blends can increase die wall friction; chromium nitride or titanium nitride coated dies are used when ejection force exceeds 350 N.

For oral granules filled into sachets, the milled granules are combined with a coated API fraction to reduce bitterness. A top-spray fluid bed coater with Wurster insert, inlet air 55°C, product temperature 32–38°C, spray rate 8–12 g/min, and atomization pressure 1.5–2.0 bar applies an ethylcellulose or methacrylate coating to a 10–15% w/w weight gain. Granules are then sieved through 1.6 mm and retained on 0.3 mm; moisture of the final sachet fill is ≤ 2.0%. Sachet fill weight is controlled to ±3% relative standard deviation; dissolution in 500 mL water at 37°C using apparatus II at 50 rpm per USP <711> must not show dose dumping if enteric coating is present. The sachet laminate is three-layer aluminum polyethylene; water vapor transmission rate below 0.1 g/m²/day at 40°C and 75% relative humidity is required to protect moisture-sensitive granules. The filled sachets are sealed at 140°C sealing jaw temperature for 1.5 s; seal strength is tested by tensile peeling to a minimum 2.5 N/15 mm width. Granule size distribution and bulk density are measured before and after packaging to detect settling during transport; bulk density of the final granule blend is maintained between 0.40 g/mL and 0.60 g/mL based on Ph. Eur. 2.9.34.